| The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1 |
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measure. |
businesswire.com |
2025-05-14 21:03:00 |
Czytaj oryginał (ang.) |
| Takeda Pharmaceuticals Caps A Strong Year, Guidance Suggests Dividend Is On The Rise |
Takeda Pharmaceuticals showed strong revenue and operating income growth in FY2024, despite challenges from Vyvanse generics and US insurance issues. New guidance for FY2025 is slightly lower due to expected deeper cuts from Vyvanse generics, but potential exists for surpassing this with new drug approvals. The dividend yield for FY2025 is projected at 4.81%, making Takeda an attractive option for income portfolios despite US healthcare market challenges. |
seekingalpha.com |
2025-05-11 12:30:00 |
Czytaj oryginał (ang.) |
| Top 4 GARP Stocks With Attractive PEG Ratios to Watch |
Here we present four high-growth GARP picks based on discounted PEG. These are PAK, FIVN, LTM and MFG. |
zacks.com |
2025-05-09 20:00:39 |
Czytaj oryginał (ang.) |
| Takeda Pharmaceutical Company Limited (TAK) Q4 2024 Earnings Call Transcript |
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q4 2024 Results Conference Call May 8, 2025 6:00 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - President & Chief Executive Officer Milano Furuta - Chief Financial Officer Andy Plump - President, R&D Julie Kim - President of the U.S. Business Unit & U.S. Country Head Giles Platford - President of the Plasma-Derived Therapies Business Unit Conference Call Participants Hidemaru Yamaguchi - Citi Shinichiro Muraoka - Morgan Stanley Stephen Barker - Jefferies Mike Nedelcovych - TD Cowen Hiroyuki Matsubara - Nomura Securities Seiji Wakao - J.P. Morgan Tony Ren - Macquarie Akinori Ueda - Goldman Sachs Fumiyoshi Sakai - UBS Christopher O'Reilly Thank you very much for taking time out of their busy schedule to join our earnings announcement for FY '24 for Takeda. |
seekingalpha.com |
2025-05-09 13:26:09 |
Czytaj oryginał (ang.) |
| Takeda Pharma less impacted by tariff, yen headwinds than other Japanese drugmakers: CEO |
Christophe Weber, CEO of Takeda Pharma, discusses the group's plans to invest $30 billion into its U.S. operations over the next five years, saying the U.S. market remain crucial for the Japanese drugmaker regardless of the global tariff tensions. |
youtube.com |
2025-05-09 03:54:40 |
Czytaj oryginał (ang.) |
| Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs |
Takeda Pharmaceutical Company Limited TAK reported a fiscal year 2024 net profit of 107.9 billion yen (around $709.86 million), down 25.1% year over year. |
benzinga.com |
2025-05-08 14:32:03 |
Czytaj oryginał (ang.) |
| Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress |
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products offsetting loss of exclusivity impact to drive revenue and Core Operating Profit growth, supported by robust cost management. Takeda has built a high-value late-stage pipeline with potentially life-transforming new treatment options for patients. Following a positive Phase 3 readout for rus. |
businesswire.com |
2025-05-08 06:36:00 |
Czytaj oryginał (ang.) |
| Takeda Pharmaceutical Co. (TAK) Upgraded to Strong Buy: Here's What You Should Know |
Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
zacks.com |
2025-05-07 17:01:00 |
Czytaj oryginał (ang.) |
| Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-05-07 14:45:49 |
Czytaj oryginał (ang.) |
| BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers |
BANNOCKBURN, Ill.--(BUSINESS WIRE)--BioLife Plasma Services, part of Takeda (TSE:4502/NYSE:TAK), today announced that it has begun introducing the new Fresenius Kabi Adaptive Nomogram across its U.S. network of plasma donation centers. The new Adaptive Nomogram is used on the Aurora Xi Plasmapheresis System, which is in more than half of BioLife's U.S. plasma donation centers. This new technology will be running in all BioLife donation centers using the Aurora Xi Plasmapheresis System by the en. |
businesswire.com |
2025-05-05 12:00:00 |
Czytaj oryginał (ang.) |
| TAK or DSNKY: Which Is the Better Value Stock Right Now? |
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY). |
zacks.com |
2025-05-02 16:41:05 |
Czytaj oryginał (ang.) |
| Are You Looking for a Top Momentum Pick? Why Takeda Pharmaceutical Co. (TAK) is a Great Choice |
Does Takeda Pharmaceutical Co. (TAK) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2025-04-30 17:01:01 |
Czytaj oryginał (ang.) |
| Best Value Stocks to Buy for April 30th |
SKM, TAK and PHIN made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 30, 2025. |
zacks.com |
2025-04-30 14:35:37 |
Czytaj oryginał (ang.) |
| Best Income Stocks to Buy for April 30th |
SKM, TAK and SONY made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 30, 2025. |
zacks.com |
2025-04-30 13:05:42 |
Czytaj oryginał (ang.) |
| Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda has awarded grants to seven nonprofits that share its commitment to creating better health for people and a brighter future for the world. |
businesswire.com |
2025-04-30 12:05:00 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for April 30th |
DB, SPOT, SONY, CIVB and TAK have been added to the Zacks Rank #1 (Strong Buy) List on April 30, 2025. |
zacks.com |
2025-04-30 09:50:32 |
Czytaj oryginał (ang.) |
| Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-04-21 14:45:59 |
Czytaj oryginał (ang.) |
| TAK vs. DSNKY: Which Stock Is the Better Value Option? |
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY). |
zacks.com |
2025-04-16 16:46:20 |
Czytaj oryginał (ang.) |
| BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3 |
LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that it has earned a 1 million USD milestone payment, following Takeda's (TSE:4502/NYSE:TAK) initiation of Phase 3 clinical trial of mezagitamab (TAK-079), identified from BioInvent's proprietary n-CoDeR® antibody library. The study is evaluating this potential best-in-class anti-CD83 monoclonal antibody for persistent or chronic primary immune thrombocytopenia (ITP). |
accessnewswire.com |
2025-04-08 11:15:00 |
Czytaj oryginał (ang.) |
| Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-04-04 14:46:48 |
Czytaj oryginał (ang.) |
| The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE) |
TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent (Aged 12 Years and Above) and Adult Patients with HAE.1 The Pre-Filled Pen Option is Designed to Allow for An Individualized Treatment Approach for Adolescent and Adult HAE Patients. In the EU, TAKHZYRO is Approved for Routine Prevention of Recurrent HAE Attacks in Patients Aged 2 Years and Older.1 ZURICH , Feb. 24, 2025 /PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) announced today that the EMA has approved an additional 2 mL pre-filled pen option for TAKHZYRO® (lanadelumab) for subcutaneous administration in adolescents (aged 12 years and above) and adult patients with Hereditary Angioedema (HAE).1 The additional subcutaneous administration option expands Takeda's offering in this space, showing dedication to the HAE community while providing individualized treatment options to support patients with a life-threatening disease, by helping to reduce HAE burden and improving their Quality of Life. |
prnewswire.com |
2025-02-24 05:01:00 |
Czytaj oryginał (ang.) |
| TAK vs. DSNKY: Which Stock Is the Better Value Option? |
Investors with an interest in Medical - Drugs stocks have likely encountered both Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY). |
zacks.com |
2025-02-17 14:46:23 |
Czytaj oryginał (ang.) |
| Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-02-14 12:45:36 |
Czytaj oryginał (ang.) |
| Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued |
Takeda Pharmaceutical offers attractive dividends and has a low price/book ratio, making it appealing despite recent price drops and US policy uncertainties. The company reported strong Q3 earnings, raised full-year FY2025 guidance, and announced a new CEO and a significant share repurchase program. Revenue and operating income exceeded expectations due to a shortage of generic Vyvanse, favorable exchange rates, and reduced amortization of intangible assets. |
seekingalpha.com |
2025-01-31 10:30:00 |
Czytaj oryginał (ang.) |
| Takeda Pharmaceutical Company Limited (TAK) Q3 2025 Earnings Call Transcript |
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q3 2025 Results Conference Call January 30, 2025 5:30 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - President and Chief Executive Officer Milano Furuta - Chief Financial Officer Andy Plump - President, R&D Conference Call Participants Stephen Barker - Jefferies Hidemaru Yamaguchi - Citi Mike Nedelcovych - TD Cowen Hiroyuki Matsubara - Nomura Securities Tony Ren - Macquarie Shinichiro Muraoka - Morgan Stanley Seiji Wakao - J.P. Morgan Hiroshi Wada - SMBC Nikko Kazuaki Hashiguchi - Daiwa Securities Miki Sogi - Bernstein Fumiyoshi Sakai - UBS Christopher O'Reilly [Foreign Language] Let me start, I'd like to remind everyone that we'll be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
seekingalpha.com |
2025-01-30 18:45:14 |
Czytaj oryginał (ang.) |
| Suffolk Celebrates Topping off for a Game-Changing New Takeda Facility in Kendall Square Where Science, Art and Community Will Converge |
BOSTON--(BUSINESS WIRE)--Suffolk, one of the largest and most innovative real estate and construction enterprises in the country, recently celebrated topping off 585 Kendall. Designed by CBT Architects, 585 Kendall is a mixed-use lab/office building and performing arts center in the Canal District of Kendall Square. The event recognized the construction teams that played a vital role in reaching this significant milestone. Takeda has leased the property's approximately 600,000-square-foot of la. |
businesswire.com |
2025-01-30 11:00:00 |
Czytaj oryginał (ang.) |
| Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026 |
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda's U.S. Business Unit, as the successor to Christophe Weber, Takeda's president, chief executive officer (CEO) and representative director, when Mr. Weber retires from the company in June 2026. Mrs. Kim will be proposed as a candidate for election to the Board at Takeda's Annual General Shareho. |
businesswire.com |
2025-01-30 04:04:00 |
Czytaj oryginał (ang.) |
| Japan's Takeda says Q3 profit slid 38%, trailing analyst estimates |
Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates, as the company continues a restructuring push. |
reuters.com |
2025-01-30 03:43:10 |
Czytaj oryginał (ang.) |
| Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth |
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advancement of its Growth & Launch Products, which delivered double-digit growth of 14.6% at CER. The company has upgraded its full year outlook for growth, reflecting strong year-to-date product performance and OPEX efficiencies, as well as revised foreign exchange assumptions. Takeda continues to adva. |
businesswire.com |
2025-01-30 03:35:00 |
Czytaj oryginał (ang.) |
| Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653) |
- Neurocrine Obtains Exclusive Worldwide Development and Commercialization Rights Excluding Japan and Converts to Royalty-Bearing License for Osavampator - Takeda Reacquires Rights to Osavampator in Japan SAN DIEGO , Jan. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the amended agreement, Neurocrine will obtain exclusive rights for all indications to develop and commercialize osavampator, a potential first-in-class AMPA positive allosteric modulator in development for patients with inadequate response to treatment of major depressive disorder (MDD) in all territories worldwide except Japan, where Takeda will reacquire exclusive rights. |
prnewswire.com |
2025-01-27 18:05:00 |
Czytaj oryginał (ang.) |
| Takeda-backed Ascentage Pharma aims to raise $126 mln in US IPO |
Ascentage Pharma said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable Chinese firm to seek a listing in the U.S. this year. |
reuters.com |
2025-01-23 21:14:21 |
Czytaj oryginał (ang.) |
| Takeda-backed Ascentage Pharma targets $1.75 billion valuation in US IPO |
China-based Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering in the United States. |
reuters.com |
2025-01-21 08:24:48 |
Czytaj oryginał (ang.) |
| Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia |
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with agammaglobulinemia or hypogammaglobulinemia1, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency (PID) or secondary immu. |
businesswire.com |
2024-12-27 03:00:00 |
Czytaj oryginał (ang.) |
| Takeda Pharmaceutical: Dividend Yield Is High But Hides Pitfalls Especially For US Investors |
Takeda Pharmaceutical offers a high dividend yield, but its sustainability is questionable due to exchange rate risks and a payout ratio often exceeding 100%. Despite growth in segments like Livtencity and Qdenga, high debt and weak currency make Takeda a risky dividend investment. The devaluation of the yen against the dollar significantly impacts revenue growth and dividend stability for U.S. investors. |
seekingalpha.com |
2024-12-07 10:00:00 |
Czytaj oryginał (ang.) |
| Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst |
On Tuesday, Takeda Pharmaceutical Company Limited TAK entered into an exclusive licensing agreement with Keros Therapeutics, Inc. KROS to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau. |
benzinga.com |
2024-12-03 14:37:24 |
Czytaj oryginał (ang.) |
| Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics |
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (Nasdaq: KROS) to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau. Elritercept is a late-stage investigational activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes (MDS) and myelo. |
businesswire.com |
2024-12-03 09:00:00 |
Czytaj oryginał (ang.) |
| Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform |
TOKYO & BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK “Takeda”) to develop Takeda's proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK). Alloy will focus on accelerating. |
businesswire.com |
2024-11-20 13:30:00 |
Czytaj oryginał (ang.) |
| Hennessy Japan Fund's Masa Takeda on the top Japanese stocks investors should watch |
Masa Takeda, portfolio manager at Hennessy Japan Fund, joins CNBC's 'Power Lunch' to discuss why he's bullish on Japan, what president-elect Trump's proposed tariffs could mean for Japanese companies, and more. |
youtube.com |
2024-11-15 17:33:39 |
Czytaj oryginał (ang.) |
| Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call Transcript |
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q2 2025 Earnings Call October 31, 2024 6:00 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - President and Chief Executive Officer Milano Furuta - Chief Financial Officer Andy Plump - President, R&D Ramona Sequeira - President, Global Portfolio Julie Kim - President, U.S. Business Unit Giles Platford - President, PDT Business Unit Teresa Bitetti - President, Global Oncology Business Unit Conference Call Participants Steve Barker - Jefferies Mike Nedelcovych - TD Cowen Tony Ren - Macquarie Miki Sogi - Bernstein Christopher O'Reilly Thank you for taking time out of your very busy schedule to join the FY ‘24 Q2 earnings announcement by Takeda. I'm the master of ceremony, Head of IR. |
seekingalpha.com |
2024-11-01 01:02:09 |
Czytaj oryginał (ang.) |
| Japan's Takeda returns to Q2 profit as drugmaker recovers from impairments |
Japan's Takeda Pharmaceutical returned to profitability in the second quarter following large impairment losses a year earlier and is restructuring to cut costs. |
reuters.com |
2024-10-31 04:15:52 |
Czytaj oryginał (ang.) |
| Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook |
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in its Growth & Launch Products driving growth. The company has upgraded its full year forecasts and Management Guidance to reflect stronger than anticipated first-half performance (including milder than anticipated generic erosion of VYVANSE® in the U.S.) and revised foreign exchange assumptions. T. |
businesswire.com |
2024-10-31 04:05:00 |
Czytaj oryginał (ang.) |
| Takeda Pharmaceuticals: An Interesting Option For Income Investors |
Takeda Pharmaceuticals (NYSE: TAK) offers a strong cash position and above-average dividend yield, making it an attractive option for income investors seeking international pharma exposure. The company's price/book value of 0.92 suggests it may be undervalued, presenting a potential long-term investment opportunity at a modest price. Risks include foreign currency exchange rate fluctuations and global pressure to reduce drug prices, which could impact profitability and margins. |
seekingalpha.com |
2024-10-07 13:36:09 |
Czytaj oryginał (ang.) |
| TAK or CTLT: Which Is the Better Value Stock Right Now? |
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks is more attractive to value investors? |
zacks.com |
2024-10-03 16:46:13 |
Czytaj oryginał (ang.) |
| Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-10-03 14:46:25 |
Czytaj oryginał (ang.) |
| Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development |
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaboration with Takeda (TSE:4502/NYSE:TAK) that takes a data-first approach to research and development, with the aim of enhancing Takeda's oncology research and development efforts. After an initial collaboration that leveraged Tempus' de-identified multimodal datasets, this new agreement will expand upon. |
businesswire.com |
2024-09-26 12:30:00 |
Czytaj oryginał (ang.) |
| Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer |
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has received approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market FRUZAQLA Capsules 1mg/5mg (generic name: fruquintinib), a selective oral inhibitor of vascular endothelial growth factor receptor (VEGFR) -1, -2 and -3, for the treatment of advanced or recurrent colorectal cancer (CRC) that is neither curable nor resectable and that has progressed after chem. |
businesswire.com |
2024-09-24 07:00:00 |
Czytaj oryginał (ang.) |
| Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries |
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE: TAK) today committed JPY4.6 billion (Approx. USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners as part of the company's ongoing commitment to improving health systems resiliency in low and middle-income countries around the world. This commitment demonstrates Takeda's focus on tackling systemic disparities and supporting local leadership in strengthening health infrastructure, empowering h. |
businesswire.com |
2024-09-18 14:00:00 |
Czytaj oryginał (ang.) |
| TAK vs. STVN: Which Stock Is the Better Value Option? |
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors? |
zacks.com |
2024-09-17 16:41:10 |
Czytaj oryginał (ang.) |
| Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-09-17 14:46:39 |
Czytaj oryginał (ang.) |
| US allows increased production of Takeda's ADHD drug to address shortage |
The U.S. Drug Enforcement Administration (DEA) has increased the production limit for Takeda Pharmaceutical's ADHD drug Vyvanse and its generic versions by about 24% to address the medicine's ongoing shortage in the United States. |
reuters.com |
2024-09-04 11:00:43 |
Czytaj oryginał (ang.) |
| Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues |
Monday, the FDA approved Ascendis Pharma A/S' ASND Yorvipath (palopegteriparatide; developed as TransCon PTH) for hypoparathyroidism in adults. |
benzinga.com |
2024-08-12 14:42:45 |
Czytaj oryginał (ang.) |
| Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday? |
Takeda Pharmaceutical Co Ltd TAK stock is trading higher on Wednesday. Earlier today, the European Commission approved Takeda's Adzynma (recombinant ADAMTS13) for treating ADAMTS13 deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cTTP). |
benzinga.com |
2024-08-07 18:29:04 |
Czytaj oryginał (ang.) |